BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that Spiro Rombotis, President and Chief Executive Officer, is scheduled to present at the 2024 BIO CEO & Investor Conference taking place in-person at the New York Marriott Marquis on February 26-27, 2024. The Company’s presentation is scheduled for Monday ...

As filed with the Securities and Exchange Commission on February 7, 2024 Registration Statement No. 333-276623 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 AMENDMENT NO. 1 TO FORM S-1 (IRS Employer Identification No.) REGISTRATION STATEMENT under the SECURITIES ACT OF 1933 CYCLACEL PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 3826 91-1707622 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classifica ...

As filed with the Securities and Exchange Commission on February 7, 2024 Registration Statement No. 333-276623 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT under the SECURITIES ACT OF 1933 CYCLACEL PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 3826 91-1707622 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (IRS Employer Id ...

BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Brian Schwartz, M.D. will assume the role of interim Chief Medical Officer ("CMO") of the Company effective immediately. Dr. Schwartz will succeed Mark Kirschbaum, M.D., whose employment was terminated by the Company. "We are delighted to have B ...

As filed with the Securities and Exchange Commission on January 19, 2024 Registration Statement No. 333- (State or other jurisdiction of incorporation or organization) Delaware 3826 91-1707622 (Primary Standard Industrial Classification Code Number) (IRS Employer Identification No.) 200 Connell Drive, Suite 1500 Berkeley Heights, NJ 07922 (908) 517-7330 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-1 REGISTRATION STATEMENT under the SECURITIES ACT OF 1933 CYCLACEL PHARMACEUTIC ...

As filed with the Securities and Exchange Commission on January 19, 2024 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-1 REGISTRATION STATEMENT under the SECURITIES ACT OF 1933 CYCLACEL PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorporation or organization) Delaware 3826 91-1707622 (Primary Standard Industrial Classification Code Number) (IRS Employer Identification No.) 200 Con ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission file number 000-50626 CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as sp ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Results Conference Call November 13, 2023 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President, CEO Paul McBarron - EVP, Finance & COO Mark Kirschbaum - SVP, CMO Conference Call Participants Ahu Demir - Ladenburg Thalmann Jonathan Aschoff - ROTH MKM Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Third Quarter 2023 Results Conference Call and Webcast. [Operator Instructions] Please note, today's call is being reco ...

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Grace Kim - Investor Relations Spiro Rombotis - President and Chief Executive Officer Mark Kirschbaum - Senior Vice President and Chief Medical Officer Paul McBarron - Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants Ahu Demir - Ladenburg Thalmann Jeff Jones - Oppenheimer Kemp Dolliver - Brookline Capital Markets Operator Good a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission file number 000-50626 CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as specifi ...